ABSTRACT
Hypoxia is related to poor prognosis because it is associated to chemo- and radioresistance. During recent years the evolution of imaging methods like PET/CT and MRI has meant the appearance of new perspectives with direct implications in radiation therapy. We discuss previous experiences in staging, planning and in the follow-up process with these techniques for measuring tumour hypoxia (AU)
Subject(s)
Humans , Animals , Male , Female , Hypoxia/metabolism , Molecular Imaging/methods , Neoplasms/diagnosis , Neoplasms/radiotherapy , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Hypoxia/genetics , Fluorodeoxyglucose F18 , Immunohistochemistry , Neoplasms/metabolism , Positron-Emission Tomography/methods , Positron-Emission Tomography , Prognosis , Radiotherapy Planning, Computer-Assisted/methodsABSTRACT
OBJECTIVE: To retrospectively evaluate the toxicity of low-dose-rate brachytherapy and to relate it to the dose-volume to organs at risk. MATERIAL AND METHODS: We study 160 patients with early prostate cancer, treated with (125)-I implants. Most of them were T1c (63.1%), T2a (35.6%) and Gleason < or =6 (96.2%). Median PSA was 7.2 ng/ml (2.3-13.5); 85.6% were lowrisk cases and 14.4% high-risk cases. Mean follow-up was 24 months (7-48). RESULTS: Acute urinary toxicity related to urological quality of life (UQL=CVU) was tolerable in 75% and unsatisfactory in 25%. Urinary retention was present in 6.9%. IPSS, V100 and D90 were related to the urinary toxicity grade. Rectal toxicity (RTOG) G2 was 0.6%. Sexual potency showed no changes with regard to the basal in 69%. Actuarial biochemical control was 89.8% at four years. CONCLUSIONS: Brachytherapy with (125)-I seeds yields acceptable toxicity and excellent biochemical control.
Subject(s)
Brachytherapy/adverse effects , Prostate-Specific Antigen/radiation effects , Prostatic Neoplasms/radiotherapy , Urination Disorders/etiology , Aged , Humans , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Prostate-Specific Antigen/blood , Quality of Life , Retrospective Studies , Sexual Dysfunction, Physiological/epidemiology , Sexual Dysfunction, Physiological/etiology , Urinary Tract/radiation effects , Urination Disorders/epidemiologyABSTRACT
OBJECTIVE: To retrospectively evaluate the toxicity of low-dose-rate brachytherapy and to relate it to the dose-volume to organs at risk. MATERIAL AND METHODS: We study 160 patients with early prostate cancer, treated with (125)-I implants. Most of them were T1c (63.1%), T2a (35.6%) and Gleason < or =6 (96.2%). Median PSA was 7.2 ng/ml (2.3-13.5); 85.6% were lowrisk cases and 14.4% high-risk cases. Mean follow-up was 24 months (7-48). RESULTS: Acute urinary toxicity related to urological quality of life (UQL=CVU) was tolerable in 75% and unsatisfactory in 25%. Urinary retention was present in 6.9%. IPSS, V100 and D90 were related to the urinary toxicity grade. Rectal toxicity (RTOG) G2 was 0.6%. Sexual potency showed no changes with regard to the basal in 69%. Actuarial biochemical control was 89.8% at four years. CONCLUSIONS: Brachytherapy with (125)-I seeds yields acceptable toxicity and excellent biochemical control (AU)
No disponible
No disponible
